Comparative efficacy of gut microbiota-targeted therapies for motor and non-motor symptoms in Parkinson's disease: a systematic review and network meta-analysis
- 1Department of Nursing, Jiang Xi Cancer Hospital
Abstract
Background: Gut dysbiosis may contribute to Parkinson's disease (PD) through the microbiota-gut-brain axis. Probiotics, synbiotics, and fecal microbiota transplantation (FMT) have been studied as potential treatments, but their comparative effects remain uncertain.
Methods: We searched trial registries and electronic databases from inception to April 1, 2026 for randomized controlled trials of gut microbiota-targeted therapies in PD. We performed a frequentist network meta-analysis. Risk of bias was assessed with Cochrane RoB 2, and confidence in the evidence was assessed with CINeMA. Treatment rankings were summarized using SUCRA values.
Results: Nineteen RCTs involving 1,156 participants and five treatment options (FMT, probiotics, synbiotics, routine care, and placebo) were included. Probiotics increased spontaneous bowel movement (SBM) frequency compared with placebo (MD = 1.93, 95% CI: 0.23 to 3.64; SUCRA = 88.3%). In the oral-administration subgroup, probiotics (MD = 2.01, 95% CI: 0.64 to 3.39) and synbiotics (MD = 1.23, 95% CI: 0.01 to 2.45) increased SBM frequency. No active treatment significantly improved MDS-UPDRS III scores compared with placebo, although synbiotics and FMT had higher SUCRA rankings. Evidence certainty was Moderate for oral probiotics on SBM frequency and Low to Very Low for motor function and quality of life.
Conclusion: Oral probiotics improved SBM frequency in patients with PD. Evidence for motor function and quality of life was uncertain, and the higher rankings of FMT and synbiotics should be considered exploratory. Larger head-to-head randomized trials are needed.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard .
Related
- Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses
- Comparative efficacy and safety of targeted disease-modifying therapies in adults with primary IgA nephropathy: a systematic review and network meta-analysis
- Peripheral Neuropathy in Parkinson’s Disease Treated with Device-Assisted Therapies: How Often It Is Reported Depends on How It Is Sought. A Systematic Review and Meta-Analysis
- Efficacy of combined therapies on degenerative joint disease of the temporomandibular joint: A systematic review and meta-analysis
- Efficacy of nutraceuticals as adjunctive therapies in autoimmune diseases: A systematic review of clinical trials.
BibTeX
@article{yang2026comparative,
title = {{Comparative efficacy of gut microbiota-targeted therapies for motor and non-motor symptoms in Parkinson's disease: a systematic review and network meta-analysis}},
author = {Xiaoyuan Yang and Yuanping Li and Qinghong Hu and Xuan Pan and Jinhua Hong and Lu Li},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1907410},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1907410/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparative efficacy of gut microbiota-targeted therapies for motor and non-motor symptoms in Parkinson's disease: a systematic review and network meta-analysis
AU - Xiaoyuan Yang
AU - Yuanping Li
AU - Qinghong Hu
AU - Xuan Pan
AU - Jinhua Hong
AU - Lu Li
PY - 2026
DA - 2026/10/26
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1907410
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1907410/full
AB - Background: Gut dysbiosis may contribute to Parkinson's disease (PD) through the microbiota-gut-brain axis. Probiotics, synbiotics, and fecal microbiota transplantation (FMT) have been studied as potential treatments, but their comparative effects remain uncertain. Methods: We searched trial registries and electronic databases from inception to April 1, 2026 for randomized controlled trials of gut microbiota-targeted therapies in PD. We performed a frequentist network meta-analysis. Risk of bias was assessed with Cochrane RoB 2, and confidence in the evidence was assessed with CINeMA. Treatment rankings were summarized using SUCRA values. Results: Nineteen RCTs involving 1,156 participants and five treatment options (FMT, probiotics, synbiotics, routine care, and placebo) were included. Probiotics increased spontaneous bowel movement (SBM) frequency compared with placebo (MD = 1.93, 95% CI: 0.23 to 3.64; SUCRA = 88.3%). In the oral-administration subgroup, probiotics (MD = 2.01, 95% CI: 0.64 to 3.39) and synbiotics (MD = 1.23, 95% CI: 0.01 to 2.45) increased SBM frequency. No active treatment significantly improved MDS-UPDRS III scores compared with placebo, although synbiotics and FMT had higher SUCRA rankings. Evidence certainty was Moderate for oral probiotics on SBM frequency and Low to Very Low for motor function and quality of life. Conclusion: Oral probiotics improved SBM frequency in patients with PD. Evidence for motor function and quality of life was uncertain, and the higher rankings of FMT and synbiotics should be considered exploratory. Larger head-to-head randomized trials are needed. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard .
SN - 1664-302X
ER -